Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BESIDE: Budesonide Oral Gel in EoE
NCT05214599Phase 2Withdrawn
- Sponsor
- Bazell Pharma AG
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of EPI-EE in eosinophilic esophagitis (EoE), sponsored by Bazell Pharma AG. Planned start Apr 2021; status: withdrawn.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05214599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214599.